Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advancing Strategies for Proteolysis-Targeting Chimera Design
Minglei Li, Ying Zhi, Bo Liu, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2308-2329
Closed Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Theranostic Fluorescent Probes
Amit Sharma, Peter Verwilst, Mingle Li, et al.
Chemical Reviews (2024) Vol. 124, Iss. 5, pp. 2699-2804
Open Access | Times Cited: 123
New-generation advanced PROTACs as potential therapeutic agents in cancer therapy
Chao Wang, Yujing Zhang, Wujun Chen, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 27
Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
Qiao‐Hong Chen, Erick Munoz, Dennis Ashong
Cancers (2024) Vol. 16, Iss. 3, pp. 663-663
Open Access | Times Cited: 15
Current advances and development strategies of orally bioavailable PROTACs
Shenxin Zeng, Yingqiao Ye, Heye Xia, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115793-115793
Closed Access | Times Cited: 35
Stimuli-activatable PROTACs for precise protein degradation and cancer therapy
Jing Gao, Lei Yang, Shumin Lei, et al.
Science Bulletin (2023) Vol. 68, Iss. 10, pp. 1069-1085
Closed Access | Times Cited: 34
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
Nikol A. Zografou-Barredo, Alex J. Hallatt, J. S. JUN. RICCI, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 88-89, pp. 117334-117334
Open Access | Times Cited: 31
Discovery of Novel PROTAC Degraders of p300/CBP as Potential Therapeutics for Hepatocellular Carcinoma
Qi Chang, Jiayi Li, Yue Deng, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 4, pp. 2466-2486
Closed Access | Times Cited: 12
Drug Discovery Targeting Nuclear Receptor Binding SET Domain Protein 2 (NSD2)
Zonghui Ma, Andrew A. Bolinger, Haiying Chen, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 16, pp. 10991-11026
Open Access | Times Cited: 20
Design, Synthesis, and Biological Evaluation of Novel EGFR PROTACs Targeting C797S Mutation
Yasheng Zhu, Xiuquan Ye, Yuxing Wu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 7283-7300
Closed Access | Times Cited: 7
Accelerating PROTACs Discovery Through a Direct‐to‐Biology Platform Enabled by Modular Photoclick Chemistry
Ke‐Nian Yan, Yong‐Qiang Nie, Jiayu Wang, et al.
Advanced Science (2024) Vol. 11, Iss. 26
Open Access | Times Cited: 7
Recent Progress in DNA Damage Response-Targeting PROTAC Degraders
Binbin Cheng, Xiaoting Fei, Zongbao Ding, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 9, pp. 6906-6921
Closed Access | Times Cited: 6
The Quest for Oral PROTAC drugs: Evaluating the Weaknesses of the Screening Pipeline
Giulia Apprato, Giuseppe Ermondi, Giulia Caron
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 7, pp. 879-883
Open Access | Times Cited: 14
Rational Design of Bioorthogonally Activatable PROTAC for Tumor-Targeted Protein Degradation
Tao Bi, Liang Pan, Yanan Zhou, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 21, pp. 14843-14852
Closed Access | Times Cited: 14
Use of Aldehyde–Alkyne–Amine Couplings to Generate Medicinal Chemistry-Relevant Linkers
Andrew McGown, Vesna Vetma, Damien Crépin, et al.
ACS Medicinal Chemistry Letters (2025)
Open Access
A Comprehensive Primer and Review of PROTACs and Their In Silico Design
Jacopo Zattoni, Paola Vottero, Gea Carena, et al.
Computer Methods and Programs in Biomedicine (2025) Vol. 264, pp. 108687-108687
Open Access
PROTAC-loaded nanocapsules degrading BRD4 for radio-chemotherapy sensitization in glioblastoma
Yun Guo, Mingzhu Fang, Shilin Zhang, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
Advancements in Proteolysis Targeting Chimeras for Targeted Therapeutic Strategies in Alzheimer’s Disease
Qiuzhi Zhou, Weixia Wang, Chunchu Deng
Molecular Neurobiology (2025)
Open Access
Design and Evaluation of a Low Hydrogen Bond Donor Count Fragment Screening Set to Aid Hit Generation of PROTACs Intended for Oral Delivery
Benjamin C. Whitehurst, Matthias R. Bauer, Fredrik Edfeldt, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 11, pp. 7594-7604
Closed Access | Times Cited: 11
Discovery of a Highly Potent and Selective BRD9 PROTAC Degrader Based on E3 Binder Investigation for the Treatment of Hematological Tumors
Haiting Duan, Jingyu Zhang, Renzhao Gui, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 13, pp. 11326-11353
Closed Access | Times Cited: 4
RIPTACs: A groundbreaking approach to drug discovery
Zonghui Ma, Andrew A. Bolinger, Jia Zhou
Drug Discovery Today (2023) Vol. 28, Iss. 11, pp. 103774-103774
Open Access | Times Cited: 9
Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK)
Zhaozhao Wang, S. Qu, Jiahao Yuan, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 96, pp. 117514-117514
Closed Access | Times Cited: 9
Targeted degradation of zDHHC-PATs decreases substrate S-palmitoylation
Mingjie Bai, Emily Gallen, Sarah Memarzadeh, et al.
PLoS ONE (2024) Vol. 19, Iss. 3, pp. e0299665-e0299665
Open Access | Times Cited: 3
Computational methods and key considerations for in silico design of proteolysis targeting chimera (PROTACs)
Amr E. Abbas, Fei Ye
International Journal of Biological Macromolecules (2024) Vol. 277, pp. 134293-134293
Closed Access | Times Cited: 3
Small molecules targeting HDAC6 for cancer treatment: Current progress and novel strategies
Ziqian Huang, Ling Li, Binbin Cheng, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 178, pp. 117218-117218
Open Access | Times Cited: 3
Discovery of an activatable near-infrared fluorescent and theranostic PROTAC for tumor-targeted detecting and degrading of BRD4
Keliang Li, Guoqiang Dong, Shanchao Wu, et al.
Chinese Chemical Letters (2024), pp. 110280-110280
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top